| Lin LH |
------>authors3_c=None ------>paper_class1=1 ------>Impact_Factor=None ------>paper_class3=2 ------>paper_class2=1 ------>vol=52 ------>confirm_bywho=shanghf ------>insert_bywho=lucie ------>Jurnal_Rank=None ------>authors4_c=None ------>comm_author= ------>patent_EDate=None ------>authors5_c=None ------>publish_day=None ------>paper_class2Letter=None ------>page2=857 ------>medlineContent= ------>unit=E0104 ------>insert_date=20041013 ------>iam=4 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN=None ------>authors_c=None ------>score=500 ------>journal_name=Chem. Pharm. Bull. ------>paper_name=Effects of Cantharidinimides on Human Carcinoma Cells ------>confirm_date=20041014 ------>tch_id=066003 ------>pmid=15256708 ------>page1=855 ------>fullAbstract=Modification of the cantharidinimide structure led to the discovery of a novel class of antitumor compounds. These cantharidinimide derivatives containing aliphartic, aryl, and pyridyl groups showed some effect in vitro against HepG2 and HL-60 cells. ------>tmu_sno=None ------>sno=9872 ------>authors2=Huang HS ------>authors3=Lin CC ------>authors4=Lee LW ------>authors5=Lin PY ------>authors6= ------>authors6_c=None ------>authors=Lin LH ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c=None ------>publish_area=None ------>updateTitle=Effects of cantharidinimides on human carcinoma cells. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no=7 ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2004 ------>submit_flag=None ------>publish_month=None |